Senseonics And TypeZero Sign Development Agreement For Artificial Pancreas And Decision Support Systems

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and TypeZero Technologies, Inc., a personalized diabetes management company, today announced the signing of a research and development license agreement to develop artificial pancreas and decision support systems that use the Eversense CGM System.

“We’re thrilled to partner with TypeZero with the goal of progressing the diabetes management field in providing solutions to help minimize the burden of diabetes for millions of people”

The goal of the agreement is to integrate glucose readings from the Eversense CGM System into TypeZero’s inControl software platform, which includes decision support and artificial pancreas system solutions. Combined with insulin data, the continuous glucose readings from the Eversense sensor will equip TypeZero’s artificial pancreas algorithms to automatically adjust and regulate insulin delivery via a user’s insulin pump. The integration will also enable TypeZero’s decision support system to recommend optimal basal and bolus doses for insulin pen users.

“We’re thrilled to partner with TypeZero with the goal of progressing the diabetes management field in providing solutions to help minimize the burden of diabetes for millions of people,” says Tim Goodnow, President and CEO of Senseonics. “It is particularly gratifying that the combined Eversense and inControl platform is intended to be used by either insulin pumpers or insulin pen users. The continuous long-term use of an accurate sensor such as Eversense combined with the clinically proven treatment algorithms of inControl has the promise of impacting both pump and pen users in a positive and meaningful way.”

The non-exclusive agreement marks the first effort to combine a CGM sensor that lasts up to 90 days with smart algorithms for closed loop and decision support applications. Clinical development and evaluation of the inControl with Eversense application is in the initial discussion phase.

“We see the combination of our inControl technology with Senseonics’ sensor as potentially a huge win for persons with diabetes,” said Chad Rogers, CEO of TypeZero. “In many ways CGM data is the heartbeat of our artificial pancreas and decision support technologies, and integrating our inControl platform with the reliable and durable Eversense CGM System which could give patients yet another tool for managing their health and simplifying their lives.”

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation continuous glucose monitoring (CGM) system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.

About TypeZero Technologies, Inc.

The world leader in clinically tested artificial pancreas solutions, TypeZero Technologies is a digital health and personalized diabetes management company dedicated to revolutionizing the treatment and management of diabetes. TypeZero is combining next-generation data science techniques, proven metabolic models, and modern engineering practices to develop customized analytics tools and blood glucose control solutions to help people with diabetes improve their health and lives. TypeZero’s current solutions include a smartphone-based artificial pancreas system, therapy optimization tools for health care providers, and advisory applications for smart insulin pens. To learn more, visit www.typezero.com.

Forward Looking Statements

Certain statements contained in this press release, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements.” These forward-looking statements reflect Senseonics’ current views about its plans, intentions, expectations, strategies and prospects, including statements concerning the potential integration of readings from Eversense CGM system into TypeZero’s inControl software platform and the potential development of an artificial pancreas. Although Senseonics believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, Senseonics can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond Senseonics’ control. Other risks and uncertainties are more fully described in the section entitled “Risk Factors” in Senseonics’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 23, 2017 and its other SEC filings. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made in this press release speak only as of the date stated herein, and subsequent events and developments may cause Senseonics’ expectations and beliefs to change. While Senseonics may elect to update these forward-looking statements publicly at some point in the future, Senseonics specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.